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Abstract The structural basis of the antifracture eYcacy
of strontium ranelate and alendronate is incompletely
understood. We compared the eVects of strontium ranelate
and alendronate on distal tibia microstructure over 2 years
using HR-pQCT. In this pre-planned, interim, intention-to-
treat analysis at 12 months, 88 osteoporotic postmeno-
pausal women (mean age 63.7 § 7.4) were randomized to
strontium ranelate 2 g/day or alendronate 70 mg/week in a
double-placebo design. Primary endpoints were changes in
microstructure. Secondary endpoints included lumbar
and hip areal bone mineral density (aBMD), and bone
turnover markers. This trial is registered with http://www.
controlled-trials.com, number ISRCTN82719233. Baseline
characteristics of the two groups were similar. Treatment
with strontium ranelate was associated with increases in
mean cortical thickness (CTh, 5.3%), cortical area (4.9%)
and trabecular density (2.1%) (all P < 0.001, except cortical
area P = 0.013). No signiWcant changes were observed with
alendronate. Between-group diVerences in favor of stron-
tium ranelate were observed for CTh, cortical area, BV/TV
and trabecular density (P = 0.045, 0.041, 0.048 and 0.035,
respectively). aBMD increased to a similar extent with
strontium ranelate and alendronate at the spine (5.7% ver-
sus 5.1%, respectively) and total hip (3.3% versus 2.2%,
respectively). No signiWcant changes were observed in
remodeling markers with strontium ranelate, while suppres-
sion was observed with alendronate. Within the methodo-
logical constraints of HR-pQCT through its possible
sensitivity to X-ray attenuation of diVerent minerals, stron-
tium ranelate had greater eVects than alendronate on distal
tibia cortical thickness and trabecular volumetric density.
Keywords Biochemical markers · Bone mineral density · 
Cortical bone · Microstructure · Trabecular bone
Introduction
Bone fragility increases as age advances because of the
appearance of abnormalities in bone remodeling [1]. The
negative balance between the relatively greater volume of
bone resorbed by osteoclasts than that subsequently depos-
ited by osteoblasts in the basic multicellular unit (BMU)
combined with a high rate of bone remodeling produce tra-
becular thinning, loss of trabeculae, cortical porosity and
cortical thinning [2].
Several agents reduce the risk of fractures in women
with postmenopausal osteoporosis [3]. However, the
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partly reverse bone fragility are not completely understood,
in part, because non-invasive techniques for measuring
them have only recently become available [4–6]. DeWning
these changes is important because only a small proportion
of the fracture risk reduction with antiresorptives is
accounted for by the increase in aBMD. Indeed, aBMD
does not capture the contribution of the reduction in cortical
and trabecular thinning, or intra-cortical porosity that may
occur in response to therapy [2, 7].
The antiresorptive agent alendronate reduces the rate of
remodeling by about 60% [8]. Following initiation of treat-
ment, steady state is perturbed as many cavities excavated
by high remodeling before treatment partly Wlled by bone
formation while 40% fewer new BMUs in their resorptive
phase appear [9]. The result of this perturbation is a net
rapid increase in aBMD with alendronate [10]. However,
no longitudinal in vivo data in humans are available to
determine the microstructural changes that accompany this
modiWcation. In cross-sectional studies on single bone
biopsies from postmenopausal osteoporotic women, alendr-
onate preserves existing architecture but has not been
reported to improve or restore the architectural integrity of
bone [11–13]. Bone strength has been shown to increase in
monkeys after treatment with alendronate [14].
Strontium ranelate does not reduce the rate of bone
remodeling as assessed by dynamic histomorphometry
[15]. It does increase in vitro pre-osteoblastic cell replica-
tion and osteoblastic diVerentiation with mineralized nod-
ule formation [16, 17]. Exposure of cells to strontium
ranelate in vitro increases the ratio of osteoprotegerin to
receptor activator of nuclear factor kappa B ligand (OPG/
RANKL) in the medium, while treatment of cells reduces
resorption in calvaria [18, 19]. However, there is no in vivo
evidence for a reduction in volume of bone resorbed by
osteoclasts or an increase in mean wall thickness (a mea-
sure of the volume of bone formed by the BMU) with stron-
tium ranelate [15]. Nevertheless, CT analysis on unpaired
biopsies from patients treated for 3 years with strontium
ranelate suggests a higher cortical thickness and trabecular
number than in the placebo group [15]. Results on 4 paired
iliac crest bone biopsies from postmenopausal osteoporotic
women from a 3-year phase III study suggest that these
changes might be due to improvement in trabecular and
cortical bone microstructure [15], an observation requiring
conWrmation in larger-scale studies. There is also evidence
for improvements in bone strength with strontium ranelate
[20].
The development of non-invasive methods for quantify-
ing bone microstructure has made it possible to study the
early changes in bone structure that may, in part, explain
fracture risk reductions observed with antiosteoporotic
agents [5, 6]. We compared the eVects of strontium ranelate
and alendronate, both of which have demonstrated antifrac-
ture eYcacy [21–23], on bone microstructure of the distal
tibia and distal radius using HR-pQCT in a pre-speciWed
interim analysis at 1 year, in a trial lasting 2 years.
Materials and methods
Study design
In this randomized, double-blind, double-dummy, two-year
study, patients were randomly assigned (1:1) to strontium
ranelate 2 g/day or alendronate 70 mg/week. All received
calcium (500 mg) and vitamin D (400 IU) supplementation.
Compliance was deWned as the number of sachets taken
divided by the theoretical number of sachets to be taken.
Patients were ambulatory Caucasian women, aged ¸50, at
least 5 years after menopause with a lumbar, femoral neck,
or total hip T-score ·¡2.5. The main exclusion criteria
were body mass index (BMI) >30 or <18 kg/m2, diseases
and treatments that interfere with bone metabolism (bis-
phosphonate for more than 1 year, strontium ranelate or
glucocorticoids in the previous year, calcitonin within pre-
vious 6 months, or hormone replacement therapy within
previous 3 months), oesophageal disease, and patients at
risk of venous thrombo-embolism. This trial is registered
with http://www.controlled-trials.com, number ISRCTN8
2719233. The protocol was approved by local ethics com-
mittees and followed ethical principles stated in the Decla-
ration of Helsinki, 1964, amended Edinburgh 2000. All
women gave their written informed consent prior to partici-
pation.
HR-pQCT techniques
HR-pQCT (Xtreme CT, Scanco Medical AG, Bruttisellen,
Switzerland) examinations were performed at baseline, at 3
and 6 months, and then every 6 months at the non-domi-
nant distal tibia and distal radius. For tibia, the reference
line was set at the distal joint limit and for the radius at the
most proximal location of the sub-chondral plate. The
region of interest (ROI) consisted of 110 slices measured
proximally to a 22.5-mm point from the reference line for
the tibia and at 9.5 mm for the radius. Scans were read cen-
trally (Scanco Medical AG). The central facility was blind
to treatment assignment. Scan quality was rated as follows:
very good quality, exam without any movement artifacts;
good quality, minor movement artifacts not aVecting the
integrity of the cortical circumference; medium quality,
clearly visible movement artifacts with horizontal streaks at
cortical edge; poor quality, marked movement artifacts with
disruption in cortical edge and image partially blurred; and
very poor quality, completely blurred images. A scan was123
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quality. Daily quality controls were centrally reviewed, and
cross-calibration of the devices was performed using a
density phantom and an anthropomorphic phantom (a non-
human bone specimen prepared by Dr M. A Krieg,
Lausanne, Switzerland) to follow the stability of both
density and structural parameters.
The methods used to process and validate the HR-pQCT
data have been reported elsewhere [5, 6]. In brief, cortical
and trabecular compartments were separated by segmenta-
tion using a low-pass Wlter. The threshold to determine cor-
tical bone from trabecular bone was set at 1/3 of the
apparent cortical bone density value [24]. Cortical thick-
ness (CTh) was the mean cortical volume divided by the
outer bone perimeter. Trabecular bone density (Dtrab, tra-
becular volumetric BMD) was computed as the average
mineral density within the trabecular volume of interest.
Trabecular bone volume fraction (BV/TV) was derived
from Dtrab (BV/TV = 100 £ Dtrab/1200). Trabecular
number (TbN) was evaluated using the Ridge number [5].
TbN was the inverse of mean spacing of the mid-axes. Het-
erogeneity of the trabecular network (Tb.1/N.SD) was eval-
uated measuring the SD of the individual distribution of the
trabeculae separation. Trabecular thickness (TbTh) and
separation (TbSp) derived from BV/TV and TbN:TbTh =
(BV/TV)/TbN and TbSp = (1 ¡ BV/TV)/TbN [1]. Perios-
teal perimeter and cross-sectional area (CSAtotal, mm²) of
the tibia and radius were used to match the volumes of
interest on the baseline and follow-up scans. Area of the
cortical bone (CSAcort) and the trabecular bone (CSAtrab)
was calculated. For follow-up, only the bone volume com-
mon to all assessable scans was used to assess density and
microstructure. Common region was 93.0% (range, 74–99;
median, 94.0%).
Other analyses
Total hip, femoral neck and lumbar aBMD was measured
by dual-energy X-ray absorptiometry (DXA) using Hologic
or Lunar devices at baseline, at 1 and 2 years. Baseline val-
ues are means of two examinations. A cross-calibration
program was performed throughout the study (Dr M-A
Krieg). Bone markers were assessed at baseline, 3 and
6 months, and then every 6 months over 2 years. The bone
formation marker bone alkaline phosphatase (b-ALP), and
the bone resorption marker C-telopeptides crosslinks of
type-1 collagen (S-CTX) were centrally assessed (Supreme,
Liège, Belgium). b-ALP was assayed by immunoradiomet-
ric assay (Tandem®-ROstase®, Beckman Coulter, San
Diego, CA, USA), and S-CTX was assayed using an
enzyme-linked immunosorbent assay (Serum Cross-
Laps®ELISA, Nordic Bioscience Diagnostic, Herlev, Den-
mark). Adverse events were recorded at each study visit.
Full blood cell count, creatinine, blood calcium and blood
strontium were measured at all visits.
Statistical analysis
The study was exploratory. No formal sample size calcula-
tion was performed. However, a calculation of the study
power was conducted and showed that, with a risk  = 0.05,
the statistical power to detect a diVerence was 86% for CTh
and 70% for Dtrab. An interim pre-planned analysis was
performed at 1 year while maintaining the blinding for the
sponsor, investigator and patients. All eYcacy analyses
were performed in intention-to-treat (ITT) and included
randomized patients having taken at least one dose of study
medication, with a baseline and postbaseline assessable
HR-pQCT scans. All analyses were performed on non-cali-
brated data. For the tibia, 92% of the patients had at least
two scans rated as good or very good quality. For the
radius, 28% of the examinations were not satisfactory.
Criteria analyzed were as follows: TbN, Tb.Th, TbSp, CTh,
Tb.1/N.SD, BV/TV, Dcort (cortical volumetric BMD), Dtrab
(trabecular volumetric BMD), CSAtotal, CSAtrab and
CSAcort.
Relative change from baseline to last observation (end)
at the 1-year visit was analyzed with a linear model with
center as covariate (Wxed eVect). The robustness of this
main analysis was veriWed using the same model with cen-
ter as random eVect. Moreover, since the distribution of
HR-pQCT data is not well deWned, a second robustness
analysis was performed using a non-parametric approach
without adjustment based on Hodges-Lehmann’s estimator.
This type of non-parametric approach avoids hypotheses on
the normality of the distribution of the data usually made in
the parametric model.
Treatment eVect was analyzed using a Student t test or a
Wilcoxon signed-ranks test, and treatment groups were
then compared using Student t test based on the overall
general linear model (least-squares norm) or with a Mann–
Whitney Wilcoxon test when appropriate. The within-
group results are presented as means § SD or median when
non-normally distributed, and between-group diVerences
are presented as estimates § SE. Similar analyses were per-
formed for aBMD and bone turnover markers. Safety was
analyzed using descriptive statistics. The type I error rate
was set at 5%.
Correlation between cortical thickness and bone strontium 
content
To evaluate a possible inXuence of bone strontium content
on CTh measurement by computerized tomography, we
analyzed the correlation between CTh and bone strontium
content in 10 biopsies from postmenopausal women123
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SOTI and TROPOS trials [15, 21, 22, 25]. In brief, the
embedded biopsy blocks were examined at 20 m isotro-
pic resolution using a CT scanner (CT 40, Scanco Med-
ical AG, Bruettisellen, Switzerland). Mineralized bone
was separated from bone marrow with a 3D segmentation
algorithm. CTh was calculated as the average thickness of
the 3D cortex from the inner to the outer cortical surfaces
of the biopsy specimens. For measurement of bone stron-
tium, a part of the embedded bone biopsies was subjected
to nitric acid/perchloric acid digestion at high tempera-
ture. Total bone calcium and strontium concentrations
were measured by inductively coupled plasma optical
emission spectrometry using a vacuum polychromator.
Total bone strontium content was calculated and
expressed as the ratio Sr/Sr + Ca. In addition, we analyzed
the correlation between distal tibia cortical thickness and
area, and serum strontium levels, as a surrogate of bone
strontium content, since there were no bone biopsies col-
lected in the present trial.
Role of the funding source
Servier funded this study. Statistical analyses were sub-
contracted by Servier to Biotrial (Rennes, France). Data
concerning HR-pQCT, biochemical markers and blood
strontium were collected centrally by independent cen-
ters and transferred to Biotrial for statistical analysis.
BMD print-outs were sent directly from the investigator
centers to Biotrial and data captured. Remaining data
collected in this study were held by Servier, locked, and
then transferred to Biotrial. Only Biotrial had access to
the decoding list. To maintain blinding, results of quan-
titative data analyses were given by treatment groups
(mean § SD), but minimal and maximal values, and val-
ues that could lead to the identiWcation of a patient, were
not provided. For qualitative data, only statistics on the
whole population were provided. All authors reviewed
the manuscript and jointly agreed to submit the Wnal ver-
sion of the manuscript. The corresponding author had
access to all the data and had the Wnal responsibility for
the decision to submit the manuscript.
Results
The two groups had comparable baseline characteristics
(Table 1). Of 88 patients randomized, 75 (85%) completed
the Wrst year and 85 (97%) were included in the ITT popu-
lation. Compliance was ¸80% in 93% of subjects. Treat-
ment duration and exposure were similar in the two groups.
For the tibia, at 12 months, Dcort increased by 1.1 §
2.7% (P = 0.005) with strontium ranelate but not with
alendronate (0.5 § 2.0%, P = 0.114). Dcort was 758.9 §
86.0 mg HA/cm3 with strontium ranelate and 749.6 §
78.0 mg HA/cm3 with alendronate (Table 2). CTh
increased by 5.3 § 0.2% in the strontium ranelate group
(P < 0.001) but was unchanged in the alendronate group
(1.3 § 6.0%, P = 0.13). The between-group diVerence in
favor of strontium ranelate was 3.9 § 1.9% (P = 0.045).
The increase in CTh with strontium ranelate was
2.9 § 4.9% at 3 months versus baseline (P < 0.001) and
was 2.3 § 0.9% (P = 0.012) greater than in the alendronate
group (Fig. 1). The increase in CTh was associated with a
signiWcant increase in cortical area by 4.9 § 9.8% over
12 months (from 74.4 § 22.1 to 77.4 § 21.8 mm²,
P = 0.013) and by 2.9 § 4.8% over 3 months (from 74.4 §
22.1 to 75.9 § 21.7 mm², P < 0.001). No signiWcant
changes in cortical area were observed in the alendronate
group over 1 year (1.1 § 5.6%, 74.0 § 21.2 to 74.8 §
21.6 mm², P = 0.178). The estimated between-group diVer-
ence (SE) was 1.1 § 0.4% (P = 0.009) at 3 months and
3.8 § 1.8% (P = 0.041) at 1 year.
Table 1 Baseline characteristics
Values are mean § SD
BMI body mass index; BMD bone mineral density; BV/TV bone vol-
ume fraction; CSA cross-sectional area (total, trabecular, or cortical);
CTh cortical thickness; D bone density (trabecular or cortical); TbN
trabecular number; TbSp trabecular separation; TbTh trabecular thick-
ness; Tb.1/N.SD heterogeneity of the trabecular network
Strontium 
ranelate 
(n = 44)
Alendronate 
(n = 44)
Number of subjects 44 44
Age (years) 63.7 § 7.3 63.8 § 7.6
Height (cm) 160 § 6 158 § 6
Weight (kg) 59.3 § 9.2 56.5 § 7.6
BMI (kg/m²) 23.1 § 3.3 22.6 § 2.7
L1-L4 BMD (g/cm²) 0.759 § 0.093 0.745 § 0.097
Lumbar T-score ¡2.6 § 0.8 ¡2.7 § 0.8
Femoral neck BMD (g/cm²) 0.625 § 0.110 0.614 § 0.103
Femoral neck T-score ¡1.9 § 0.9 ¡2.0 § 0.7
Dcort (mg HA/cm3) 750.8 § 86.8 745.8 § 77.9
CTh (m) 723 § 240 752 § 262
BV/TV (%) 94 § 25 93 § 27
DTb (mg HA/cm3) 113.3 § 30.3 111.9 § 32.0
TbN (mm¡1) 1.36 § 0.33 1.25 § 0.29
TbSp (m) 680 § 268 714 § 190
TbTh (m) 68 § 15 73 § 17
Tb.1/N.SD 0.41 § 0.34 0.42 § 0·23
CSAtotal (mm²) 679 § 106 627 § 115
CSAcort (mm²) 74.4 § 2.2 74.0 § 21.2
CSAtrab (mm²) 594 § 111 542 § 123123
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and Dtrab by 2.1 § 5.2% (both P = 0.002) in the strontium
ranelate group (Fig. 1). These changes were signiWcant
from 6 months (BV/TV, 0.9 § 2.3%, P = 0.031; Dtrab,
0.9 § 2.2%, P = 0.033). No signiWcant changes were
observed in the alendronate group. The estimated between-
group diVerences were 1.7 § 0.8% (P = 0.048) for BV/TV
and 1.8 § 0.8% (P = 0.035) for DTrab. TbN increased in the
strontium ranelate and alendronate groups, (4.2 § 8.2%,
P = 0.011, and 4.3 § 10.7%, P = 0.030, respectively) with
a corresponding decrease in trabeculae spacing (TbSp;
¡3.7 § 8.3%, P = 0.001, and ¡3.1 § 9.8%, P = 0.031)
with no signiWcant between-group diVerences. TbTh
remained unchanged with strontium ranelate (¡1.6 §
8.6%, P = 0.096) but decreased with alendronate (¡2.8 §
8.3%, P = 0.024), and this was signiWcant from 3 months
(¡3.4 § 7.5%, P = 0.007). The heterogeneity of the trabec-
ular network decreased with strontium ranelate
(¡3.6 § 8.6%, P = 0.007), signiWcantly from 6 months
(¡3.2 § 8.1%, P < 0.017) but remained unchanged with
alendronate (¡1.9 § 12.2, P = 0.361). There was no
between-group diVerence. Trabecular area decreased at
12 months in the strontium ranelate group (¡0.34 §
0.42%, from 594 to 592 mm², P < 0.001) but not in the
alendronate group (¡0.11 § 0.42%, from 542 to 541 mm²,
P = 0.097). The estimated between-group diVerence was
¡0.22 § 0.10% (P = 0.024). Similar results were found at
3 months.
Out of 88 patients, only 63 (72%) had assessable distal
radius examinations, mainly due to movement artifacts. Of
these patients, the relative changes in structural parameters
evaluated by HR-pQCT was ·1% for strontium ranelate
and alendronate, respectively (mean relative change at M12
in CTh: +0.3 § 6.2% and ¡1.1 § 5.8%; Dcort: 0.9 § 2.1%
Table 2 Relative change (%) from baseline to end of microstructure parameters at the distal tibia
P values <0.05 (signiWcant) are in bold
SE standard error; CI conWdence interval; BV/TV bone volume fraction; CSA cross-sectional area (total, trabecular, or cortical); CTh cortical thick-
ness; D bone density (trabecular or cortical); TbN trabecular number; TbSp trabecular separation; TbTh trabecular thickness; Tb.1/N.SD heteroge-
neity of the trabecular network
a P < 0.05 versus baseline
Change from baseline (%) [mean § SD (min; max)] Between-group diVerence
Strontium ranelate Alendronate Estimate (SE) 95%CI P value
Dcort 1.13 § 2.7a (¡7.8;8.8) 0.54 § 2.0 (¡4.9; 4.7) 0.65 (0.51) [¡0.37; 1.67] 0.210
CTh 5.3 § 10.2a (¡10.5;59.5) 1.3 § 6.0 (¡14.5; 14.6) 3.90 (1.92) [0.09; 7.72] 0.045
BV/TV 2.0 § 5.3a (¡23.5;11.6) 0.6 § 3.6 (¡8.3; 10.7) 1.67 (0.83) [0.01; 3.32] 0.048
Dtrab 2.1 § 5.2a (¡22.0;12.2) 0.6 § 3.8 (¡8.6; 11.1) 1.76 (0.82) [0.13; 3.39] 0.035
TbN 4.2 § 8.2a (¡20.8;20.0) 4.3 § 10.7a (¡17.3; 34.4) 0.05 (2.07) [¡4.06; 4.17] 0.980
TbSp ¡3.7 § 8.3a (¡17.0;25.4) ¡3.1 § 9.8a (¡26.1; 22.5) ¡0.65 (1.98) [¡4.59; 3.29] 0.743
TbTh ¡1.6 § 8.6 (¡17.5;28.8) ¡2.8 § 8.3a (¡24.0; 17.6) 1.25 (1.92) [¡2.58; 5.07] 0.518
Tb.1/N.SD ¡3.6 § 8.6a (¡26.3;22.0) ¡1.9 § 12.2 (¡36.7; 43.3) ¡1.87 (2.35) [¡6.54; 2.08] 0.428
CSAtot 0.01 § 0.02 (0.0;0.1) 0.01 § 0.02 (0.0; 0.1) 0.00 (0.0) [¡0.01; 0.01] 0.996
CSAcort 4.9 § 9.8a (¡11.5;57.4) 1.1 § 5.6 (¡13.2; 13.2) 3.80 (1.83) [0.15; 7.45] 0.041
CSAtrab ¡0.34 § 0.42a (¡2.0;0.4) ¡0.11 § 0.42 (¡0.9; 1.1) ¡0.22 (0.1) [¡0.41; ¡0.03] 0.024
Fig. 1 Change in cortical thick-
ness (CTh) (a) and relative tra-
becular bone volume (BV/TV) 
(b) over time (mean § sem) in 
the strontium ranelate and 
alendronate groups
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4.4%; Dtrab: ¡0.4 § 3.6% and ¡0.6 § 4.2%; TbN: ¡0.1 §
5.9% and ¡0.1 § 5.3%; TbTh: 0.1 § 6.7% and ¡0.3 § 6.1%;
TbSp: 0.4 § 6.1% and 0.3 § 5.6%; CSAtot: 0.0 § 0.2% and
0.1 § 0.2; CSAcort: 0.4 § 5.7% and ¡0.8 § 6.0%; CSAtrab:
0.2 § 1.0% and ¡0.4 § 0.9%). A slight increase in cortical
density was signiWcant in the strontium ranelate group
(P = 0.015) but not in the alendronate group (P = 0.577).
The estimated between-group diVerence was 0.95 § 0.47%
(P = 0.05). There were no other signiWcant within- or
between-group diVerences (data not shown).
The mean bone strontium content from biopsies sampled
in postmenopausal women after 3 years of treatment from
the SOTI and TROPOS studies was 1.8%, four times more
than at 1 year. No correlation was detected between CTh
and bone strontium content (r2 = 0.003, y = ¡30.03x +
816). Similarly, there was no correlation between distal
tibia cortical thickness and area, and serum strontium levels
(r2 = 0.235; P = 0.134 and r2 = 0.241; P = 0.124 respec-
tively).
Lumbar, total hip and femoral neck aBMD increased in
both groups and did not diVer between groups (Table 3). In
the strontium ranelate group, b-ALP increased by a median
of 0.55 ng/mL (+4.1%, P = 0.095) at 3 months and 0.6 ng/mL
(+5%, P = 0.082) at 12 months. S-CTX remained unchanged
(median, ¡0.04 ng/mL, ¡7%, P = 0.250). In the alendro-
nate group, both b-ALP and S-CTX decreased (median,
¡4.7 ng/mL, ¡35%, P · 0.001, and ¡0.36 ng/mL, ¡58%,
P < 0.001, respectively). Between-group diVerences at
1 year were 40 and 55%, respectively (P · 0.001 each)
(Fig. 2).
Adverse events were analyzed in pooled groups to main-
tain blinding. One patient withdrew because of develop-
ment of a peptic ulcer and one for upper abdominal pain.
Both events were considered as related to the study drug by
the investigator. Four patients suVered a rash, three were
considered as possibly or doubtfully related to the study
drug; all were mild, one led to treatment withdrawal. Two
patients had an increase in CPK judged clinically signiW-
cant by the investigator, one case at 6 months that sponta-
neously recovered on treatment and one case at 12 months.
Both values were lower than three times the upper limit of
the normal range.
Discussion
To our knowledge, this is the Wrst head-to-head, double-
blind, randomized controlled trial comparing eVects of
strontium ranelate and alendronate on bone microstructure.
Strontium ranelate increased cortical thickness, cortical
area and trabecular density after 1 year of treatment. Tra-
becular bone volume and density increased with a decrease
in the heterogeneity of the trabecular network. No change
Table 3 Relative change in 
areal bone mineral density 
(aBMD) from baseline to end 
(mean § SD)
Change in aBMD (g/cm²) Between-group diVerence
Strontium 
ranelate
Alendronate Estimate 
(SE)
95%CI
Lumbar 5.7 § 4.4a 5.1 § 4.7a 0.4 (1.0) [¡1.64; 2.47]
Femoral neck 3.6 § 4.1a 2.8 § 3.4a 0.8 (0.8) [¡0.91; 2.47]
Total hip 3.3 § 3.6a 2.2 § 2.8a 1.0 (0.7) [¡0.47; 2.41]
SE standard error; CI conWdence 
interval
a P < 0.001 versus baseline
Fig. 2 Change from baseline 
over time (median, Q1 and Q3) 
of b-ALP (a) and S-CTX (b) in 
the strontium ranelate and 
alendronate groups
b
0,1
** **
a
2
-0,1
0 6 12 
months
0.40 ng/mL
50%months-1
0
1
6 12
0 4
-0,3
-0,2 a a a5.82 ng/mL
40%
-3
-2
a
a
a
-0,6
-0,5
- ,
***
***
***
-6
-5
-4
***
***
***
Alendronate 70 mg/ week Strontium ranelate 2g/day
** p value intra group < 0 05
***  p-value intra-group < 0.001
    -  -  
 
.
a p-value inter-group < 0.001123
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thickness, cortical area, and BV/TV and decrease in trabec-
ular bone area were greater in the strontium ranelate than in
the alendronate group. Trabecular number increased in both
groups.
While these results suggest that strontium ranelate has a
positive eVect on bone microstructure, they require cautious
interpretation given changes in tissue mineralization may
modify the attenuation characteristics of photons during
HR-pQCT imaging [26]. Both drugs might artifactually
increase edge detection. Strontium ranelate has twice the
atomic number of calcium and alendronate increases the
mean degree of mineralization [27]. Cortical thickening
suggests that there is an increase in periosteal and/or endo-
cortical bone formation but neither can be conWrmed as
endocortical perimeter was not available with the HR-
pQCT technique used in this study, while periosteal perim-
eter (a measure of periosteal apposition) and total cross-
sectional area are used to match the volumes of interest
between baseline and postbaseline exams. Moreover, corti-
cal area may increase without change in periosteal or endo-
cortical perimeters if there is Wlling of intracortical pores
with mineralized bone. This will also result in an apparent
increase in the cortical thickness given it is calculated as
cortical area/perimeter [28].
While these possibilities cannot be excluded, bone stron-
tium content is low after 1 year (0.43 § 0.28%, n = 8) [25].
After 3 years treatment, with a strontium content of 1.8%,
four times more than at 1 year, strontium is present in only
37% of the bone surface and mainly trabecular surfaces
[25]. Furthermore, after 3 months of treatment, when bone
strontium content is plausibly lower (2.2% of the bone area
with strontium and 0.14% of strontium in bone) [25],
increases in cortical thickness, cortical area and BV/TV are
already observed in the strontium ranelate group, making
less likely that the changes observed are entirely due to the
higher atomic number of strontium and issues concerning
edge detection. Furthermore, we did not detect any positive
correlation between cortical thickness and area, and serum
strontium levels.
We also performed a simulation to quantify the possible
inXuence of strontium content on X-ray linear attenuation
in the evaluation of CTh (A. Laib, Scanco Medical AG,
personal communication). Calculations were based on the
results of Boivin and colleagues [25] who quantiWed, in
bone biopsies of patients treated for 2 or 3 years with stron-
tium ranelate 2 g/day, the strontium content in cortical bone
(newly formed and “old” bone) and the percentage of bone
area containing strontium. We also used the linear attenua-
tion coeYcients (mu/rho) of cortical bone, of calcium and
of strontium given by the National Institute of Standards
and Technology (http://physics.nist.gov/PhysRefData/Xray
MassCoef/cover.html). We calculated the percentage of
strontium after 1 year of treatment in the cortical bone and
estimated the variation of X-ray linear attenuation due to
the replacement of calcium atoms by this quantity of stron-
tium atoms. This led to an increase in linear attenuation
coeYcient of 0.255%.
Then, we electronically changed the pixel values of the
cortex pixels to increase them by the estimated 0.255%, and
processed the scans again. The resulting CTh was 0.49%
higher than the initially measured CTh.
This means that a small part of the increase in cortical
thickness in strontium ranelate group could be related to
strontium dependent overestimation of the measurement.
Trabecular volumetric BMD increased in the strontium
ranelate group due to an increase in trabecular number not
thickness. This was associated with a corresponding
decrease in trabecular spacing and an improvement of the
trabecular homogeneity consistent with improved trabecu-
lar architecture. These observations may also be the result
of changes in attenuation characteristics. Trabeculae that
were not detectable at baseline may have become detect-
able due to an increase in edge detection. This possibility
would also account for the increase in TbN in the alendro-
nate group without a change in BV/TV as alendronate
increases secondary mineralization (even though no
increase in tissue density was detected at 1 year) by sup-
pressing remodeling [11, 13]. This could also explain the
apparent decrease observed in trabecular thickness since
this parameter is derived from TbN.
The groups were similar in terms of baseline characteris-
tics, including HR-pQCT parameters. The increases in
aBMD in the two groups were similar to those previously
observed [21–23]. The results on bone markers are also in
accordance with published data. The changes in b-ALP
with strontium ranelate were of a similar magnitude to
those observed in the SOTI study [21]. The lack of signiW-
cance in the present study may be due to a small sample
size and a great inter-patient variation for the change from
baseline to end. In the alendronate group, the decrease in S-
CTX by roughly 60% preceded the decrease in b-ALP, as
demonstrated elsewhere [29].
Within the constraints imposed by methodological issues
described earlier, with strontium possibly inXuencing X-ray
attenuation, we infer that strontium ranelate improved bone
microstructure within 3 months, while alendronate pre-
serves existing structures. The observed changes in struc-
ture and density using strontium ranelate require
conWrmation with larger sample sizes and using dynamic
histomorphometry.
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